Search results
Retina UK recently launched an innovative course, Discover Wellbeing, to help those living with inherited sight loss develop an awareness of emotional wellbeing and practical skills to adapt to life’s ups and downs.
A recently published study has described numerous disease mechanisms that appear to be common across different types of inherited sight loss, suggesting that there is significant potential for drug treatments that could work regardless of the underlying causative gene.
It’s not very often that we come across a researcher working on a project inspired by their own lived experience of a sight loss condition.
A discovery made as part of research funded by Retina UK has led to a prestigious award of $2.5 million, enabling scientists to undertake more in-depth investigations and work towards a treatment for a particular type of retinitis pigmentosa.
Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.
It is important to avoid harming your vision, particularly if you have an inherited sight loss condition.
Our Keynote speaker will be Mr Kanmin Xue. Mr Xue is a Consultant Vitreo-retinal Surgeon at the John Radcliffe Hospital and Wellcome Trust clinician scientist fellow at the University of Oxford where he leads the Retinal Disease and Repair Group.
Retina UK invites expressions of interest for their inaugural career development grant call, which will result in an award of up to £1million as a strategic and targeted investment to result in a transformative impact for therapy for inherited retinal dystrophy.
Dr Graham undertook research into the basic mechanisms of retinal vasculitis, inflammation of the blood vessels in the retina, and is an important cause of poor vision in patients with uveitis, inflammation of the uveal tract.
Hajrah Sarkar is a PhD student whose project is funded by Retina UK.
